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A mitochondrial based oncology platform for targeting cancer stem cells (CSCs):
MITO-ONC-RX
Federica Sotgiaa, Bela Ozsvaria, Marco Fiorillo a,b, Ernestina Marianna De Francesco a,b, Gloria Bonuccellia,
and Michael P. Lisantia
aTranslational Medicine, School of Environment and Life Sciences, Biomedical Research Centre (BRC), University of Salford, Greater
Manchester, UK; bDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy
ABSTRACT
Here, we wish to propose a new systematic approach to cancer therapy, based on the targeting of
mitochondrial metabolism, especially in cancer stem cells (CSCs). In the future, we envision that
anti-mitochondrial therapy would ultimately be practiced as an add-on to more conventional
therapy, largely for the prevention of tumor recurrence and cancer metastasis. This mitochondrial
based oncology platform would require a panel of FDA-approved therapeutics (e.g. Doxycycline)
that can safely be used to inhibit mitochondrial OXPHOS and/or biogenesis in CSCs. In addition,
new therapeutics that target mitochondria could also be developed, to optimize their ability to
eradicate CSCs. Finally, in this context, mitochondrial-based biomarkers (i.e. “Mito-signatures”)
could be utilized as companion diagnostics, to identify high-risk cancer patients at diagnosis,
facilitating the early detection of tumor recurrence and the prevention of treatment failure. In
summary, we suggest that new clinical trials are warranted to test and possibly implement this
emerging treatment strategy, in a variety of human cancer types. This general approach, using
FDA-approved antibiotics to target mitochondria, was effective in killing CSCs originating from
many different cancer types, including DCIS, breast (ER(+) and ER(-)), prostate, ovarian, lung and
pancreatic cancers, as well as melanoma and glioblastoma, among others. Thus, we propose the
term MITO-ONC-RX, to describe this anti-mitochondrial platform for targeting CSCs. The use of re-
purposed FDA-approved drugs will undoubtedly help to accelerate the clinical evaluation of this
approach, as these drugs can move directly into Phase II clinical trials, saving considerable
amounts of time (10–15 y) and billions in financial resources.
ARTICLE HISTORY
Received 8 June 2018
Revised 2 August 2018
Accepted 20 August 2018
KEYWORDS
Mitochondria; drug
discovery; oncology
platform; Mito-therapeutics;
Mito-signatures;
mito-biomarkers;
Mitoriboscins; Mitoketoscins;
Mitoflavoscins
1. Mitochondrial function is required for CSC
propagation
Tumors and their microenvironment are incred-
ibly heterogeneous structures, which behave like
metabolic ecosystems [1–12]. In accordance with
this cellular and metabolic heterogeneity, it is now
well accepted that more than a single type of
cancer cell exists [1–12]. For example, within a
given epithelial cancer cell line (such as MCF7),
there are “bulk” cancer cells (~ 85–95%; the major-
ity of the population), as well as various types of
progenitor cells (< 5%), and cancer stem cells
(CSCs; < 1%). CSCs and progenitor cells are
thought to be the most dangerous, as they behave
as tumor-initiating cells (TICs) in vivo and can
undergo metastasis; in contrast, “bulk” cancer
cells are largely non-tumorigenic.
Because CSCs are so “rare”, very little is actually
known about their metabolic properties. To func-
tionally enrich for CSCs, the entire cell population
can be trypsinized and seeded as a single-cell sus-
pension onto low-attachment plates [1,2]. Under
these conditions, the majority of “bulk” cancer
cells die (> 90%) via apoptosis, while only the
CSCs survive and propagate, ultimately resulting
after 5 d in the formation of 3D spheroid struc-
tures. Under these conditions, each 3D spheroid is
clonally formed from a single CSC. For breast
CSCs, these 3D spheroids are also known as
tumor-spheres or mammo-spheres [1–12]. The
generation of these 3D spheroids is thought to
mimic the process of tumor formation and/or
metastasis, providing an excellent model for drug
discovery and functional validation.
Thus, to begin to understand the potential
metabolic differences between “bulk” cancer cells
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and CSCs, we first compared cultured breast can-
cer cells grown either as monolayers or 3D spher-
oids. Then, they were subjected to profiling, via
unbiased label-free proteomics analysis [13].
As a result of this molecular comparison, it
became clear that over 60 nuclear-encoded mito-
chondrial proteins were specifically up-regulated
in 3D spheroid structures, relative to monolayer
cells processed in parallel [13]. Virtually identical
results were obtained with two distinct ER(+)
breast cancer cell lines (MCF7 and T47D; > 40
overlapping mitochondrial proteins). Informatics
analysis of the list of up-regulated mitochondrial
proteins was consistent with an increase in mito-
chondrial mass, due either to i) increased mito-
chondrial biogenesis or ii) a shut down in
mitophagy, or both. As such, these results indi-
cated that high mitochondrial mass is a new char-
acteristic feature of the CSC phenotype [13]. These
results also suggested the testable hypothesis that
CSCs are critically dependent on OXPHOS and/or
new mitochondrial biogenesis (protein transla-
tion), for their survival and propagation. In accor-
dance with this hypothesis, 3D spheroid formation
was effectively blocked using specific mitochon-
drial inhibitors, such as oligomycin, which targets
mitochondrial Complex V and shuts off ATP
synthesis [13]. However, oligomycin is quite
toxic, so it cannot be used as an anti-cancer
therapeutic.
As such, the question remains: How can we
safely target mitochondria in CSCs, without
inducing serious side effects in normal cells?
MitoTracker is a non-toxic fluorescent probe that
can be used to directly measure mitochondrial mass
in live cells by flow cytometry [14]. In order to
further validate the functional relationship between
high mitochondrial mass and “stemness”, we
employed staining with MitoTracker to metaboli-
cally fractionate the MCF7 cell line into “Mito-
high” and “Mito-low” cell sub-populations [14].
For this purpose, we used MitoTracker Deep Red
FM, which is a far-red fluorescent dye (abs/em
~ 644/665 nm) that stains mitochondria in live
cells. As predicted the “Mito-high” cell population,
with increased mitochondrial mass, showed the
greatest capacity for i) 3D spheroid formation and
ii) tumor initiation in a pre-clinical animal model in
vivo [14]. Therefore, mitochondrial mass is a critical
determinant of stemness in cancer cells. In addition,
elevated telomerase activity (hTERT), a functional
marker of proliferation and immortality in CSCs,
was also specifically associated with high mitochon-
drial mass [15].
In light of the above results, a targeted reduc-
tion in mitochondrial mass or OXPHOS should
provide a specific Achilles’ heel for the eradication
of CSCs [13–15].
2. Mitochondrial-based therapeutic
strategies for eradicating CSCs: FDA-approved
drug repurposing and natural products
Over the last several years, our laboratory has focused
on the identification and repurposing of FDA-
approved drugs that can be used to inhibit the propa-
gation of CSCs. These different antibiotics include
members of the i) Tetracycline family (Doxycycline/
Tigecycline) [16] and the ii) Erythromycin family
(Azithromycin) [16], as well as iii) anti-parasitic
drugs (Pyrvinium pamoate and Atovaquone) [16,17]
and iv) anti-microbials targeting drug-resistant myco-
bacterium (Bedaquiline; TB, tuberculosis) [18],
(Figure 1, and Table 1).
One aspect that all these antibiotics have in com-
mon is that they exert manageable anti-mitochon-
drial side-effects, which can be repurposed as their
therapeutic effects, to eradicate CSCs [19,20]. More
specifically, Doxcycyline and Azithromycin inhibit
mitochondrial protein translation, effectively block-
ing new mitochondrial biogenesis [16–20]. Since
most tissues already have large numbers of mito-
chondria (especially skeletal muscle, heart and
brain), normal cells remain unaffected. In contrast,
CSCs appear to be “addicted” to the generation of
new mitochondria, providing a novel basis for the
selectivity of these antibiotics in targeting CSCs. New
mitochondrial biogenesis may also be required for
asymmetric cell division in CSCs.
In addition, Pyrvinium pamoate and
Atovaquone behave as mitochondrial OXPHOS
inhibitors, affecting Complexes II and III [16,17].
Bedaquiline inhibits the mitochondrial ATP-
synthase (Complex V) [18]. Finally, we also iden-
tified a series of experimental and natural com-
pounds targeting CSCs, including glycolysis
inhibitors (Vitamin C and Silibinin) [20] and
mitochondrial inhibitors (Actinonin; CAPE, from
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Honey bee propolis) [20], as well as inhibitors of
protein synthesis (puromycin) and NAD(+) recy-
cling (FK-866) [20,21] (Figure 2 and 3).
As CSCs appear to be highly proliferative, due to
their over-expression of telomerase (hTERT), they
are quite sensitive to Palbociclib, an FDA-approved
CDK4/6 inhibitor, with an IC-50 of ~ 100 nM [15]
(Table 1). Therefore, inhibition of CSC proliferation
is an alternative or could be used in conjunction with
anti-mitochondrial therapy [15].
Regarding therapy with Doxycycline, one possible
concern that arises is the potential for the
development of drug-resistance in CSCs [22]. To
address this issue directly, we developed and char-
acterized the phenotypic behavior of Doxy-resistant
(DoxyR)-MCF7 cells [22]. Remarkably, what we
observed is that DoxyR-CSCs show a dramatic shift
towards aerobic glycolysis, due to a loss of mitochon-
drial function, ultimately resulting in metabolic
inflexibility [22]. As expected, they showed an up
to 35-fold loss of mitochondrial-DNA encoded pro-
teins (mt-DNA) that are absolutely required for
OXPHOS activity, such as MT-ND3, MT-CO2,
MT-ATP6 and MT-ATP8 [22]. Also, DoxyR-CSCs
appeared to be more “quiescent”, with > 50% reduc-
Table 1. FDA approved drugs successfully used to eradicate CSCs.
Drug Name Inhibition of FDA-approved Refs
Doxycycline Mito Biogenesis Yes [16,19,22]
Tigecycline Mito Biogenesis Yes [16]
Azithromycin Mito Biogenesis Yes [16]
Pyrvinium
Pamoate
OXPHOS/Complex II Yes [16]
Atovaquone OXPHOS/Complex III Yes [17]
Bedaquiline Complex V Yes [18]
Palbociclib CDK4/6 Yes [15]
a) b)
c) d)
e)
Antibiotics for Targeting Mitochondria
Figure 1. Repurposing FDA-approved antibiotics for targeting
mitochondria in CSCs. a) Doxycycline; b) Azithromycin; c)
Pyrvinium (pamoate salt; not shown); d) Atovaquone; and e)
Bedaquiline. Doxycycline and Azithromycin (a,b) are known to
inhibit mitochondrial protein translation as an off-target side effect.
They are used clinically as antibiotics to inhibit bacterial protein
synthesis. Similarly, Pyrvinium pamoate and Atovaquone (c,d) are
known to inhibit OXPHOS (related to mitochondrial complex II/III),
as a side effect. Bedaquiline (e) was originally designed to inhibit the
bacterial ATP-synthase, which is analogous to mitochondrial com-
plex V. All of these FDA-approved drugs (a-e) have been shown to
inhibit the anchorage-independent propagation of CSCs, by target-
ing mitochondrial function.
Naturally Occurring Compounds
a) b)
c)
d)
Figure 2. Natural products used for targeting CSCs. a) Caffeic
acid phenyl ester (CAPE); b) Vitamin C (Ascorbic acid); c)
Actinonin and d) Silibinin. CAPE (from bee propolis) inhibits
OXPHOS; Vitamin C blocks GAPDH (a glycolytic enzyme), which
is directly upstream of mitochondrial metabolism; Actinonin
inhibits the initiation of both bacterial and mitochondrial pro-
tein translation; Silibinin (from milk thistle) decreases glucose
uptake, by targeting the GLUT family of transporters. These
natural products all inhibit CSC expansion.
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tions in proliferation and cell migration, as well as a
significantly impaired ability to form 3D spheroids.
As a consequence, our results showed that DoxyR-
CSCs are
especially sensitive to other metabolic therapies,
including inhibitors of i) OXPHOS (Atovaquone,
Irinotecan, Sorafenib, Niclosamide), ii) glycolysis
(Vitamin C and Stiripentol) and iii) autophagy
(Chloroquine).
Importantly, many of these drugs are already
clinically-approved (Atovaquone, Irinotecan,
Sorafenib, Niclosamide, Stiripentol, Chloroquine)
or they are natural products (Vitamin C and
Berberine), making them readily available for clinical
trials (Table 2). Therefore, the efficacy of
Doxycycline could be potentially improved, by
developing combination therapies with these other
metabolic inhibitors, based on the concepts of meta-
bolic inflexibility and synthetic lethality in cancer
cells [22].
3. Mitochondrial-based therapeutic strategies
for eradicating CSCs: developing new
mitochondrial inhibitors
Because of the success of our drug repurposing
efforts, we also decided to develop a series of
new therapeutics, by focusing on key mitochon-
drial targets [23–26]. These results are briefly sum-
marized in Table 3.
As a consequence, based on in silico drug design
(i.e. computational chemistry) and phenotypic drug
screening, we identified several new families of mito-
ribosome inhibitors, termed Mitoriboscins [23],
(Figure 4). They were specifically designed to target
the mitochondrial ribosome, to inhibit mitochondrial
protein synthesis. By targeting the mitochondrial
enzymes OXCT1 and ACAT1, we also developed
new mitochondrial inhibitors that interfere with
ketone metabolism, by mimicking the structure of
CoA [24], (Figures 5 and 6). In addition, we identified
a novel approach to acutely induce a Vitamin B2
(riboflavin) deficiency, that potently inhibits CSC pro-
pagation, with an IC-50 of ~ 3 nM [25], (Figure 7,
Upper). Thus, this drug is approximately 30 times
more potent than Palbociclib for targeting CSCs.
Experimental Compounds
a)
b)
c)
Figure 3. Experimental compounds used for targeting CSCs. a) FK-
866 (NAMPT inhibitor); b) Puromycin; and c) 2-Deoxy-glucose (2-
DG). FK-866 potently inhibits the NAD(+) salvage pathway;
Puromycin inhibits protein synthesis (both cellular and mitochon-
drial), as it resembles the structure of a tRNA; 2-DG is a modified
form of glucose, in which the OH-group at the 2 position has been
removed and replaced with a hydrogen atom. As a consequence, it
cannot undergo complete glycolysis and competitively inhibits the
pathway, blocking the formation of glucose-6-phosphate from glu-
cose. These three experimental compounds all block CSC propaga-
tion, by interfering with energy metabolism.
Table 2. Nine drugs, or nutraceuticals, that were successfully
used in conjunction with Doxycycline, to eradicate CSCs.
Drug Name Target FDA-approved
Atovaquone OXPHOS Yes
Irinotecan OXPHOS Yes
Sorafenib OXPHOS Yes
Niclosamide OXPHOS Yes
Berberine OXPHOS Natural supplement
2-DG* Glycolysis Experimental
Vitamin C Glycolysis Natural supplement
Stiripentol Glycolysis Clinically-approved
(Europe/Canada/Japan)
Chloroquine Autophagy Yes
*2-deoxy-glucose; See reference [22], for additional information.
Table 3. Novel anti-mitochondrial drug design: Four new ther-
apeutic classes.
Drug Name Target Metabolic Process Refs
Mitoriboscins Mito-ribosome Mito Protein Synthesis [23]
Mitoketoscins OXCT1/ACAT1 Ketone Metabolism [24]
Mitoflavoscins Mito Complex I/II Flavin-containing proteins [25]
TPP* Mitochondria Mito-targeting-signal(s) [26]
*Tri-phenyl-phosphonium
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The use of tri-phenyl-phosphonium (TPP) also
appears to be a very promising approach, as it
behaves as a chemical mitochondrial targeting sig-
nal (MTS) (Figure 7, Lower) [26]. Interestingly, a
series of TPP compounds we tested were non-toxic
in normal fibroblasts, but were selectively toxic in
“bulk” cancer cells and CSCs [26]. Therefore, these
TPP compounds appear to be able to metabolically
distinguish between “normal cell” mitochondria
and “malignant” mitochondria [26]. Since “bulk”
cancer cells and CSCs likely have mitochondria
with higher membrane potentials, this could
explain the selective targeting of cancer cell mito-
chondria with TPP compounds.
Finally, we have begun to search for new
naturally-occurring mitochondrial inhibitors,
that can be used to more effectively target
CSCs (Table 4). In this context, we recently
showed that two molecules that are novel com-
ponents of Bergamot, namely Brutieridin and
Melitidin, act as specific Statin-like drugs and
inhibit mevolonate metabolism, as well as
CSC propagation (Figure 8) [27]. Interestingly,
Bergamot is currently used as a fragrance in
many health and well-being products (soaps
and perfumes), and is a significant component
of Earl Grey English breakfast tea.
OR
Mitoketoscins
Figure 5. Mitoketoscins: Therapeutics for targeting mitochon-
drial ketone metabolism. The pharmacaphore for Mitoketoscins
is shown. These compounds were identified by combining
computational chemistry (in silico drug design), together with
phenotypic library screening, to detect ATP depletion. The
targets used were the crystal structures of OXCT1 and ACAT1,
mitochondrial enzymes involved in the conversion of serum
ketone bodies back into Acetyl-CoA, for use in the TCA cycle.
Mitoketoscins
a)
b)
Compound 2
Compound 8
Figure 6. Mitoketoscins: Docking images with OXCT1 and
ACAT1. (a) Compound 2 docking at the succinyl-CoA binding
site of 3-oxoacid CoA-transferase 1 (OXCT1); (b) compound 8
docking at the CoA binding site of human acetyl-CoA acetyl-
transferase (ACAT1). Modified and reproduced from [24].
Mitoriboscins
O
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a) b)
c)
Figure 4. Mitoriboscins: Novel inhibitors for targeting the mito-
chondrial ribosome. Several examples of Mitoriboscins are illu-
strated. These compounds were identified by combining
computational chemistry (in silico drug design), together with
phenotypic library screening, to detect ATP depletion. The tar-
get used was the 3D structure of the large mitochondrial ribo-
some, as determined by cryo-EM (electron microscopy). For
further details on these compounds, please see reference [23].
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Interference with the normal process of
mitochondrial fission-fusion cycles, by targeting
the DRP1 protein, may also represent a new
viable strategy for eradicating CSCs (See
Figure 8 and Table 4) [28].
4. Mitochondrial inhibitors also show broad-
spectrum antibiotic activity
The identification and design of new mitochon-
drial inhibitors has other interesting medical
applications and benefits, such as the develop-
ment of new anti-bacterial and anti-fungal
agents, to combat antibiotic-resistance.
According to the “Endo-symbiotic Theory of
Mitochondrial Evolution”, mitochondria first
originated historically from the engulfment of
aerobic bacteria, an event that occurred ~ 1.45
billion years ago [29–32]. As a result, mitochon-
dria still share strong structural and functional
similarities with bacteria, explaining the off-tar-
get effects of antibiotics, which often show man-
ageable mitochondrial side-effects [29–32].
Conversely, it would then be predicted that
Mitoflavoscins
(DPI)
Tri-phenyl-phosphonium
(TPP)
R
Figure 7. Mitoflavoscins and Tri-phenyl-phosphonium (TPP).
Upper, The structure of DPI (Diphenyleneiodonium chloride), a
Mitoflavoscin, is shown. Lower, The structure of a representative
TPP compoundis is shown.
a)
b)
Bergamot Natural “Statins” and mDIVI1
c)
Figure 8. Components of Bergamot function as natural “statin-
like” molecules. The chemical structures of a) Brutieridin and b)
Melitidin are shown. The structure of c) mDIVI1 is also shown
for comparison.
Table 4. Other experimental mitochondrial inhibitors for targeting
CSCs.
Drug Name Target Metabolic Process Inhibited Refs
mDIVI1 DRP1* Mitochondrial Fission/Fusion [28]
Brutieridin HMGR** Mevalonate Metabolism; Statin-like [27]
Melitidin HMGR** Mevalonate Metabolism; Statin-like [27]
*Dynamin-related protein 1
**3-hydroxy-3-methylglutaryl-CoA-reductase.
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mitochondrial inhibitors may also show some
moderate anti-bacterial and anti-fungal side
effects [29–32].
To directly test this hypothesis, we evaluated
the anti-bacterial and anti-fungal activity of
the Mitoriboscins [23]. Interestingly, several
Mitoriboscins showed anti-bacterial activity
towards both gram-positive and gram-negative
organism(s), as well as pathogenic yeast
(Candida albicans) and even Methicillin-resistant
Staphylococcus aureus (MRSA) [23]. Therefore,
this systematic approach, using cancer cells for
initial drug screening, may also be useful for
developing new antibiotics, to combat drug-
resistant micro-organisms [23].
5. Mitochondrial-based companion
diagnostics: treatment stratification and
predicting the response to therapy
Over one thousand mitochondrial proteins are
encoded by the nuclear genome. Therefore, we
have begun to assess their potential prognostic
value as novel biomarkers and companion diag-
nostics. Our hypothesis was that the over-expres-
sion of a given mitochondrial protein in cancer
cells and CSCs may be associated with tumor
recurrence and metastasis, due to the emergence
of drug resistance, ultimately resulting in treat-
ment failure (Figure 9).
To test this hypothesis, we used an online
survival-analysis tool (known as the KM-plotter;
http://kmplot.com/analysis/) to perform Kaplan-
Meier (K-M) studies on > 400 nuclear mitochon-
drial gene transcripts, to interrogate publically
available microarray data from patients with
four distinct epithelial cancer types: i) breast, ii)
ovarian, iii) lung and iv) gastric [32,33]. This
approach allowed us to directly perform in silico
validation of these potential mitochondrial bio-
markers [33,34].
Remarkably, in all four anatomic cancer types,
we observed that the over-expression of mitochon-
drial gene transcripts was specifically associated
with poor clinical outcome. Importantly, this
Personalized Cancer
Diagnosis and Treatment
High Mito-MarkersLow Mito-Markers
“Good” Prognosis “Bad” Prognosis
Mito-based Diagnostics
Conventional
Therapy
Mitochondrial-Based
Therapies
(e.g., Doxycycline)
Conventional
Therapy
+
Figure 9. Identifying mitochondrial-based companion diagnos-
tics for more personalized cancer therapy. Briefly, mitochondrial
markers could be used to stratify cancer patients into high-risk
and low-risk groups, at diagnosis. Patients with high levels of
mitochondrial markers (“bad prognosis”) could be treated with
mitochondrial-based therapies, as an add-on to the standard of
care, in order to effectively prevent tumor recurrence, metas-
tasis and drug-resistance. Modified from [32,33].
Mito-Signature 1
RFS   N = 145
(Recurrence)
DMFS   N = 139
(Distant Metastasis)
Mito-Signature 1
HSPD1/UQCRB/MRPL15/COX17
ER+ Luminal A LN+ Tam
Figure 10. A short mitochondrial gene signature predicts tumor
recurrence and distant metastasis, in high-risk breast cancer
patients, receiving endocrine therapy. Note that high expression
of this Mito-Signature predicts treatment failure on Tamoxifen
(Tam). These represent ER-positive patients, with the luminal A
sub-type of breast cancer, who showed local lymph node metas-
tasis at diagnosis, with 10–15 y of follow-up data. RFS, recurrence-
free survival; DMFS, distant metastasis-free survival. Reproduced
with permission from [32].
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approach effectively predicted tamoxifen-resis-
tance in ER(+) breast cancer patients (Figure 10),
as well as Taxol- and Platin-resistance in ovarian
cancer patients (Figure 11) [32,33]. These results
are functionally supported by further experimental
observations demonstrating that Tamoxifen-resis-
tant MCF7 cells (TAMR) show a significant
increase in mitochondrial oxygen consumption
and ATP production [35].
Therefore, in the future, we propose that high-
risk patients could be first identified at diagnosis,
by the high expression of mitochondrial markers
or “Mito-signatures” in their primary tumors
[33,34]. Here, we define “Mito-signatures” as com-
binations of mitochondrial markers (mRNA
levels) that can be used to more accurately predict
clinical outcome in patient populations.
Then, these patients could be also treated with
existing FDA-approved antibiotics or novel mito-
chondrial therapeutics, as an add-on to conven-
tional anti-cancer therapy [33,34].
6. Other advantages of anti-mitochondrial
therapy with Doxycycline
Doxycycline shows many other interesting anti-can-
cer properties that should be further explored. For
example, Doxycycline behaves as a radio-sensitizer,
making CSCs approximately 3 to 5 times more sensi-
tive to radiation treatment [36]. In addition,
Doxycycline effectively targets hypoxic CSCs and
overcomes Paclitaxel-resistance, under conditions of
hypoxia; this may have important implications for
achieving more effective anti-angiogenic therapy
[37]. Finally, Doxycycline appears to be effective as a
mutation-independent approach for targeting CSCs,
as it inhibits both activated H-Ras (G12V) and c-Myc
oncogenes, as well as other environmental oncogenic
stimuli (mitochondrial oxidative stress/ROS), via the
specific targeting of mitochondrial biogenesis [38].
7. Conclusions
In conclusion, we propose a new, integrated, multi-
disciplinary, medical oncology platform to target can-
cer stem cells (CSCs), in most cancer types. This new
mitochondrial oncology platform, known as MITO-
ONC-RX, consists of both therapeutic and diagnostic
modalities (Figure 12). As increased mitochondrial
biogenesis and OXPHOS are key characteristics of
CSCs, we propose to target metabolism in CSCs,
using FDA drug repurposing and/or new first-in-
class therapeutics, such as the i) Mitoriboscins, the
ii) Mitoketoscins and the iii) Mitoflavoscins, as well as
iv) TPP-based compounds. In this context, we have
also discovered a series of mitochondrial markers
(companion diagnostics) for identifying and selecting
Platins Rx
Ov-Mito-Signature 3
OS N=105
(Overall Survival)
OS N=58
(Overall Survival)
Taxol Rx
Figure 11. A short mitochondrial gene signature predicts drug-
resistance and treatment failure in ovarian cancer patients. Note
that high expression of this Mito-Signature predicts treatment
failure on Platins and Taxol, in ovarian cancer patients. These
patients with serous ovarian cancer had at least 5-years of
follow-up data. Reproduced with permission from [33].
1. Mitochondrial-targeted 
Therapeutics
2. Mitochondrial-based 
Companion Diagnostics
Prevention of Tumor Recurrence, 
Metastasis and Treatment Failure 
(Drug Resistance)
MITO-ONC-RX
Prevention of 
Poor Clinical Outcome
Figure 12. A mitochondrial-based oncology platform for cancer
therapy: MITO-ONC-RX. This oncology platform would consist of
two basic components: i) Mito-therapeutics and ii) Mito-diag-
nostics. These components could then be tailored and opti-
mized, for a given cancer type.
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the high-risk cancer patient population that is most
likely to benefit from anti-mitochondrial therapy.
The essential role of mitochondria in the pro-
pagation of CSCs has now been confirmed and
extended by other laboratories, in London and at
MD Anderson Cancer Center, as well as other
institutions (See references #2 and #39, for specific
citations). In further support of this notion, please
see the following articles for further reading on the
subject [39–45].
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